Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

ClinicalTrials.gov ID: NCT05268289

Public ClinicalTrials.gov record NCT05268289. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Adaptive, Randomized, Double-blind, Dose Exploration, Parallel Group, Placebo Controlled, Multicenter Phase 2 Trial to Evaluate the Efficacy, Safety and Tolerability of LNP023 in Combination With Standard-of-care With and Without Oral Corticosteroids in Patients With Active Lupus Nephritis Class III-IV, +/- V

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.

Study identification

NCT ID: NCT05268289
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Novartis Pharmaceuticals; Industry
Enrollment: 240 participants

Conditions and interventions

Conditions

Lupus Nephritis

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 100 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 9, 2022
Primary completion: Mar 18, 2026
Completion: Sep 27, 2028
Last update posted: Jul 29, 2026

2022 – 2028

United States locations

U.S. sites: 25
U.S. states: 16
U.S. cities: 25

Facility	City	State	ZIP	Site status
AKDHC Medical Research ServicesLLC	Phoenix	Arizona	85016	Withdrawn
Kaiser Permanente Fontana	Fontana	California	92335	Withdrawn
Univ Calif Irvine	Irvine	California	92697	Withdrawn
Ronald Reagan UCLA Medical Center	Los Angeles	California	90095	Recruiting
Loma Linda University	San Bernardino	California	92408	Active, not recruiting
Olive View UCLA Medical Center	Sylmar	California	91342	Active, not recruiting
University of Colorado Denver	Aurora	Colorado	80045	Recruiting
Royal Research Corp	Hollywood	Florida	33021	Recruiting
Mayo Clinic Jacksonville	Jacksonville	Florida	32224	Recruiting
Nephrology Associates Of Central FL	Orlando	Florida	32806	Active, not recruiting
Florida Kidney Physicians	Riverview	Florida	33578	Recruiting
Nep Assoc of Northern Illinois	Hinsdale	Illinois	60521	Completed
Wichita Community Clcl Onco Program	Wichita	Kansas	67214	Recruiting
Ochsner Health System	New Orleans	Louisiana	70121	Recruiting
Johns Hopkins Hospital	Baltimore	Maryland	21287	Active, not recruiting
Brigham and Womens Hosp Harvard Med School	Boston	Massachusetts	02115	Recruiting
Mayo Clinic Rochester	Rochester	Minnesota	55905	Withdrawn
University of Nebraska Medical Center	Omaha	Nebraska	68198	Active, not recruiting
Stony Brook Internists PC	East Setauket	New York	11733	Recruiting
Cleveland Clinic Foundation	Cleveland	Ohio	44195	Recruiting
Temple University	Philadelphia	Pennsylvania	19140	Recruiting
Allegheny Health Network	Pittsburgh	Pennsylvania	15212	Withdrawn
Dallas Nephrology Associates	Dallas	Texas	75204	Active, not recruiting
Prolato Clinical Research Center	Houston	Texas	77054	Recruiting
Virginia Commonwealth University	Richmond	Virginia	23298	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 77 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05268289, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 29, 2026 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05268289 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →